OLCC Expands Recall of Cannabis E-Cig Pods in Oregon

Feb.16.2023
OLCC Expands Recall of Cannabis E-Cig Pods in Oregon
Oregon's OLCC has expanded its recall of cannabis e-pods due to the presence of synthetic cannabinoids, affecting 7,000 units.

Portland, Oregon - The Oregon Liquor Control Commission (OLCC) has announced an expansion of the recall of marijuana electronic pods.


This recall was originally announced in January 2023.


The OLCC's ongoing investigation and evaluation has found that three batches of electronic cigarette products appear to contain prohibited additives. It states that these products do not meet national standards as they contain synthetic CBN and CBC, which produce sensory effects that are distinctly different from the psychoactive effects of tetrahydrocannabinol (THC). Ohio law prohibits electronic cigarette pods from containing synthetic cannabinoids and the synthesized CBC does not meet OLCC's requirements for non-cannabis additives.


This recall involves pods sold under the Firefly Extracts or Smoke-Rite Wellness brands. The OLCC stated that 7,000 units from the recalled batches have been sold, while approximately 500 units are still present in the market.


These recalled products were produced in a factory licensed by OLCC.


The OLCC has released a list of recalled products.


Product names, production dates, and start of sales for several Firefly pods have been reported by the OLCC. The "Purple Kush 8:1" pod with label ID 5658 was produced on May 27, 2022, and went on sale on June 21, 2022. The "Suver Haze" pod with the same label ID was produced on May 24, 2022, and began selling on March 11, 2022. The "T-1" or "High CBD 8:1" pod with label ID 5658 was produced on May 19, 2022, and has been available since that date. The "Cherry Wife 8:1" or "High CBD Blend 8" pod with label ID 5658 was produced on September 9, 2021, and went on sale on February 13, 2022. The "Cherry Wife 1:1" or "High CBD Blend 1" or "High CBD Blend 1:1" pod with label ID 5658 or 344 was produced on September 9, 2021, and began selling on October 23, 2021. The "Cherry Wife 2:1" or "High CBD Blend 2" or "High CBD Blend 2:1" pod with the same label ID was produced on September 9, 2021, and went on sale on December 12, 2021. The "Cherry Wife 10:1" or "High CBD Blend 10" or "High CBD Blend 10:1" pod with label ID 5658 or 344 was produced on July 27, 2021, and began selling on August 16, 2021. The "El Jefe" or "High CBD Blend 0" pod with label ID 5658 was produced on July 15, 2021, and went on sale on July 28, 2021. The "Sour Space Candy" pod with the same label ID was produced on May 3, 2021, and began selling on May 9, 2021. The "High CBD Blend 0" pod with label ID 5658 was produced on December 1, 2020, and became available on December 24, 2020. The OLCC has instructed those who purchased these recalled products to dispose of them, but has not received any health-related complaints related to their use.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Japan’s Heated Tobacco Tax Changes Reshape Consumer Choices, Survey Reveals Impact of Price and Income
Japan’s Heated Tobacco Tax Changes Reshape Consumer Choices, Survey Reveals Impact of Price and Income
A consumer survey by Japanese heated tobacco information platform RELAZO found that rising tobacco prices and planned heated tobacco tax changes may influence smoking decisions among Japanese consumers. The survey covered 49,879 men and women aged 20 to 69 nationwide. It found that around 40% of respondents cumulatively indicated they may consider quitting when a pack reaches ¥600 (approximately US$4.1), while nearly 90% expressed potential quitting intentions at a ¥1,000 (approximately US$6.8) price level. The survey also found significant differences by income level, with lower-income respondents showing greater sensitivity to price increases.
Jul.24
Science | International Experts Propose a New Smoking Cessation Pathway, Citing Higher Quit Rates With E-Cigarettes Than Nicotine Replacement Therapy
Science | International Experts Propose a New Smoking Cessation Pathway, Citing Higher Quit Rates With E-Cigarettes Than Nicotine Replacement Therapy
A new expert paper in JAMA urges U.S. clinicians to include nicotine e-cigarettes in smoking-cessation discussions, citing higher quit rates than nicotine replacement therapy. It also stresses that products must deliver enough nicotine to replace cigarettes, dual use should be brief, and complete switching is the goal. 2Firsts argues the recommendations matter beyond clinics: public-health professionals should reassess relative risk, regulators should preserve sufficient product appeal for adult smokers, and manufacturers should focus on helping users quit cigarettes more sustainably.
SCIENCE
Aug.03 by 2Firsts Perspectives
Trump Picks White House Health Policy Aide Heidi Overton to Lead FDA, Pending Senate Confirmation
Trump Picks White House Health Policy Aide Heidi Overton to Lead FDA, Pending Senate Confirmation
U.S. President Donald Trump has chosen White House health policy aide Heidi Overton to lead the Food and Drug Administration, Bloomberg reported, citing a person familiar with the matter. Overton currently works on health policy at the White House and previously held a senior role at the America First Policy Institute. If confirmed by the Senate, she would take over an FDA that has experienced months of senior-level turnover. The agency regulates products representing roughly one-fifth of U.S. consumer spending, including e-cigarettes, drugs, vaccines and much of the food supply.
News
Aug.19
China Discloses First Criminal Case Over Counterfeit Vapes Disguised as “Medical Nebulizers” and “Zero-Nicotine” Products
China Discloses First Criminal Case Over Counterfeit Vapes Disguised as “Medical Nebulizers” and “Zero-Nicotine” Products
Chinese authorities have disclosed the country’s first reported criminal case involving counterfeit vapes marketed as “medical nebulizers” and “zero-nicotine” products. Authorities determined that the products involved were counterfeit vapes and pursued criminal charges for producing and selling counterfeit goods. According to the report, the case resulted in the seizure of 347,000 counterfeit vape pods and 53,700 vape devices, with physical goods valued at 22.13 million yuan.
Aug.04
PMI Q2 Call: ZYN Growth, IQOS Pricing and a Diverging Global Tobacco Market
PMI Q2 Call: ZYN Growth, IQOS Pricing and a Diverging Global Tobacco Market
Philip Morris International’s second-quarter earnings call offered new detail on its smoke-free strategy. Management said it would increase U.S. investment behind nicotine pouch brand ZYN, keep IQOS focused on volume before stronger pricing, and use SENTIA, DELIA, LEVIA, VEEV and ZYN to manage tax and regulatory pressure across Japan and Europe. Analysts from Goldman Sachs, Morgan Stanley, UBS and other firms also pressed PMI on profitability, market share, cigarette resilience and the durability of its global transformation over coming quarters.
Jul.24
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Three R.J. Reynolds companies are seeking to intervene in a lawsuit filed by Altria subsidiaries Helix Innovations and NJOY challenging the FDA's 2021 PMTA final rule. The companies dispute how the agency uses Acceptance and Filing reviews and completeness determinations to establish when the Tobacco Control Act's 180-day decision period begins. Reynolds has also linked prolonged PMTA reviews to competition from unauthorized vaping products. The FDA, meanwhile, has been accelerating reviews and reducing its backlog.
Sep.14